EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

This program is conducted in the EU (Germany, Austria, Norway, The Netherlands, Sweden and United Kingdom only) For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Patients chronically infected with Hepatitis C * Patients at a high risk of liver decompensation or death within 12 months if left untreated and who have no available therapeutic options Exclusion Criteria: * Patients who are \<18 years old * Patients who have contraindications to either Daclatasvir (DCV) or Sofosbuvir (SOF) * Patients who are pregnant * Creatinine clearance (CrCl) ≤ 30 mL/min (as estimated by Cockcroft and Gault formula) * Patients who are pregnant or Women of Child Bearing Potential who are not using required contraception